View Webinar

The first autologous CAR-T therapy was approved in 2017, and the industry has since gained substantial operating experience, treating tens of thousands of patients globally. Some drug sponsors have developed in-house teams to manage, improve, and maintain the infrastructure needed for these complex therapies, while others have opted to outsource these responsibilities. The supply chain for autologous CAR-T therapies has been a focus of improvement since the early trials, especially the transport of cells. Significant investment have aimed to make the supply chain more predictable and reliable. While outsourcing the supply chain to a single logistics supplier is now more feasible, active management of the supply chain remains crucial for maintaining quality and efficiency. Managing this task internally may lead to inefficiencies, especially when compared to using partners experienced in onboarding centers for multiple clients. However, some drug sponsors prefer to manage collection center qualification internally due to the specific protocols required for each autologous CAR-T therapy, ensuring tighter control over standards and processes. Attend this webinar for insights from a panel of industry experts who will discuss these developments and how the industry can continue refining its process. They will review the successes and challenges of both in-house and outsourced models based on their extensive experiences, compare various approaches to building a collection center network. and consider potential inefficiencies when approaching the task individually compared to using a partner. Attend this webinar to:

  • Gain insights into the current state of the industry regarding outsourcing versus insourcing collection center onboarding and operations
  • Explore the logistics of cell therapy logistics to support autologous cell and gene therapies
  • Understand the financial, timing, and control challenges associated with each approach
  • Discover the basic framework for evaluating whether or not outsourcing makes sense in their particular situation

Presenters

Amy Hines Vice President, Apheresis Strategy at Cryoport Systems Jeni Newman Senior Director, Operations at NMDP BioTherapies Marcel van Houten Director Global Supply Chain at Orchard Therapeutics